28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 May
 
Normal 0 21 false false false DA X-NONE X-NONE ..
29
19 May
 
Du undrer mig at flere ikke er begyndt at bekymrer sig for situationen i Grækenland. Hvad enten man ..
25
16 May
FING-B
Der er simpelthen noget som både Dig og Denne Swiftfup har misforstået. Det som i begge har misforst..
22
21 May
 
”Verdensøkonomiens nuværende vigtigste sektor må være Kinas boligmarked. Der står 50 mio. lejlighede..
20
19 May
 
Hej alle,   Herunder er alle finanshusenes vurderinger og anbefalinger af C20 selskaber + de 'Large ..
20
19 May
GEN
Mon ikke vi nærmer os de 600 efter JNJ´s præsentation i morgen - der vil komme fokus på Daratumumab ..
20
18 May
VELO
Jeg har desværre ikke tid til en længere udredning, og heller ikke til en lang dialog, men jeg er ik..
17
16 May
FING-B
xo - dog påfaldende hvor aktiv du har været i en debat om et selskab som du 'faktisk er bedøvende li..
17
18 May
BIOPOR
  Huj hej hvor det går. Endelig sker der noget med kursen. Og selskabet står også med nogle ret inte..
15
16 May
FING-B
Typisk et fjols som dig, at sige sådan i stedet for at forholde dig til det jeg skriver. 
15

Flowserve Announces Quarterly Cash Dividend of $0.18 Per Share

22/05/2015 03:52:33
DALLAS, May 21, 2015 - Flowserve Corporation, (NYSE: FLS), a leading provider of flow control products and services for the global infrastructure markets, tod..

Form 8.3 - Synergy Health Plc

21/05/2015 15:25:36
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Form 8.3 - Greene King Plc

21/05/2015 13:06:21
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
ATOS :Atos and Siemens underline the importance of Franco-German business collaboration during French Prime Minister visit of the new Atos Business Innovation & Technology Center of Munich
2
Flowserve Announces Quarterly Cash Dividend of $0.18 Per Share
3
Endurance Announces Date of Special General Meeting of Shareholders in Connection with the Acquisition of Montpelier
4
Articles of Association for Genmab A/S
5
WellCare Selected to Continue Participating in the Florida Healthy Kids Program Will Serve Nine Florida Regions Under the New Contract

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2015   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 May 2015 09:28:16
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20150519.1 - EUROWEB5 - 2015-05-22 10:28:16 - 2015-05-22 09:28:16 - 1000 - Website: OKAY